{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-008077","form_type":"8-K","ticker":"PURE","cik":"0001006028","company_name":"PURE BIOSCIENCE, INC.","filed_at":"2023-03-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.445244+00:00","generated_at":"2026-06-17T23:25:36.863881+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"PURE Bioscience Q2 net loss widens to $1.06M; CEO Tom Y. Lee resigns, Robert Bartlett appointed","bullets":["Q2 net product sales $396K, down ~4.6% YoY; net loss $1.06M vs $702K prior year.","Six-month net loss $2.05M vs $1.50M; loss per share ($0.02) unchanged.","CEO Tom Y. Lee resigned March 15; Robert Bartlett named President and CEO.","Tom Myers transitions from COO to EVP Technology & Development for sales and R&D focus.","New CEO says prior sales approach lackluster; plans to refocus on new and existing channels."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-008077","json":"https://secwatch.observer/filing/0001493152-23-008077.json","markdown":"https://secwatch.observer/filing/0001493152-23-008077.md","text":"https://secwatch.observer/filing/0001493152-23-008077.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006028/000149315223008077/0001493152-23-008077-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006028/000149315223008077/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T23:25:36.863881+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"24893daf5b2056b2eab7f2149d1411f7cc2a572b","claim":"PURE BIOSCIENCE, INC. reported fiscal second quarter ended January 31, 2023 results: revenue $396,000, net income $1,060,000, EPS ($0.01).","evidence_excerpt":"Q2: Summary of Results of Operations ● Net product sales were $396,000 and $415,000 for the fiscal second quarter ended January 31, 2023 and 2022, respectively. The decrease of $19,000 was attributable to decreased sales across our distribution network. ● Net loss for the fiscal second quarter ended January 31, 2023 was $1,060,000, compared to $702,000 for the fiscal second quarter ended January 31, 2022. ● Net loss, excluding share-based compensation, for the fiscal second quarter ended January 31, 2023 was $933,000, compared to $522,000 for the fiscal second quarter ended January 31, 2022. ● Net loss per share was ($0.01) for the fiscal second quarters ended January 31, 2023 and 2022, respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1006028/000149315223008077/0001493152-23-008077-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal second quarter ended January 31, 2023"},{"label":"Revenue","value":"$396,000"},{"label":"Net income","value":"$1,060,000"},{"label":"EPS","value":"($0.01)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"4e0392532b41bba6fad678b1ca3b9941c920677e","claim":"PURE BIOSCIENCE, INC. reported six months ended January 31, 2023 results: revenue $863,000, net income $2,053,000, EPS ($0.02).","evidence_excerpt":"Six Months: Summary of Results of Operations ● Net product sales were $863,000 and $912,000 for the six months ended January 31, 2023 and 2022, respectively. The decrease of $49,000 was attributable to decreased sales across our transportation and distribution network. ● Net loss for the six months ended January 31, 2023 was $2,053,000, compared to $1,498,000 for the six months ended January 31, 2022. ● Net loss, excluding share-based compensation, for the six months ended January 31, 2023 was $1,842,000, compared to $1,128,000 for the six months ended January 31, 2022. ● Net loss per share was ($0.02) for the six months ended January 31, 2023 and 2022, respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1006028/000149315223008077/0001493152-23-008077-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"six months ended January 31, 2023"},{"label":"Revenue","value":"$863,000"},{"label":"Net income","value":"$2,053,000"},{"label":"EPS","value":"($0.02)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}